ACP
KRON

Acuta Capital Partners’s Kronos Bio KRON Stock Holding History

Acuta Capital Partners’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-718,739
Closed -$934K – 50
2023
Q3 		$934K Buy
718,739
+403,739
+128% +$652K 0.63% 32
2023
Q2 		$542K Buy
+315,000
New +$500K 0.37% 34

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.83B AUM 20.31% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acuta Capital Partners's KRON Position: Q4 2023 in Review

Acuta Capital Partners sold out of Kronos Bio (KRON) in Q4 2023, closing a stake of 718,739 shares — an estimated $934K sold.

Acuta Capital Partners first reported a position in KRON in Q2 2023 and held it in 2 quarters. The position peaked at $934K in Q3 2023. 60 funds tracked by Wall St. Rank hold KRON as of Q4 2023.

  • Acuta Capital Partners reported no remaining Kronos Bio position as of Q4 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 718,739 Kronos Bio shares in Q4 2023, an estimated $934K.
  • Acuta Capital Partners first reported a position in Kronos Bio in Q2 2023 and held it in 2 quarters.
  • Acuta Capital Partners's Kronos Bio position peaked at $934K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Kronos Bio as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.